About the Authors
- Benoît Vokaer
-
Contributed equally to this work with: Benoît Vokaer, Louis-Marie Charbonnier
* E-mail: bvokaer@ulb.ac.be (BV); alemoine@ulb.ac.be (ALM)
Affiliation Institute for Medical Immunology, Université Libre de Bruxelles, Gosselies, Belgium
- Louis-Marie Charbonnier
-
Contributed equally to this work with: Benoît Vokaer, Louis-Marie Charbonnier
Affiliation Institute for Medical Immunology, Université Libre de Bruxelles, Gosselies, Belgium
- Philippe H. Lemaître
-
Affiliation Institute for Medical Immunology, Université Libre de Bruxelles, Gosselies, Belgium
- Chloé Spilleboudt
-
Affiliation Institute for Medical Immunology, Université Libre de Bruxelles, Gosselies, Belgium
- Alain Le Moine
-
* E-mail: bvokaer@ulb.ac.be (BV); alemoine@ulb.ac.be (ALM)
Affiliation Institute for Medical Immunology, Université Libre de Bruxelles, Gosselies, Belgium
Competing Interests
This study was partly funded by GlaxoSmithKline Biologicals. There are no patents, products in development or marketed products to declare. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.
Author Contributions
Conceived and designed the experiments: BV LMC. Performed the experiments: BV LMC PL CS. Analyzed the data: BV LMC ALM. Contributed reagents/materials/analysis tools: BV LMC PL CS ALM. Wrote the paper: BV LMC ALM. Made the figures: BV LMC. Designed and supervised research: ALM.